Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas
TISF-ctDNA is a promising biomarker for monitoring GBM recurrence and evaluating clinical benefit. It provides insight into tumor genomic evolution and identifies patients who may benefit from adjuvant chemotherapy. TISF-ctDNA positivity is a robust prognostic indicator for patient outcomes and a marker for molecular recurrence after frontline therapy.
Authors
- Chaojie Bu
- Guangzhong Guo
- Chunxiao Ma (ORCID: https://orcid.org/0000-0002-1322-2863)
- Guanzheng Liu (ORCID: https://orcid.org/0000-0002-3692-0314)
- Yushuai Gao
- Guangming Lv (ORCID: https://orcid.org/0000-0002-7669-3021)
- Jiubing Zhang (ORCID: https://orcid.org/0009-0000-2549-4068)
- Xingyao Bu (ORCID: https://orcid.org/0000-0002-1541-2185)
- Gang Liu (ORCID: https://orcid.org/0000-0001-6620-176X)
- Ziyue Zhang (ORCID: https://orcid.org/0000-0002-6050-779X)
- Zhaoyue Yan
- Ruijiao Zhao
- Dayang Wang
Institutions
- Henan University (CN)
- Zhengzhou University (CN)
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Neurosurgery
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1227/neu.0000000000003384
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.75
Funders
- Natural Science Foundation of Henan Province